Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3078-3081

  Lau, Derick H ^a   Crowley, John J ^a   Gandara, David R ^a   Hazuka, Mark B ^a   Albain, Kathy S ^a   Leigh, Bryan ^a   Fletcher, William S ^a   Lanier, Keith S ^a   Keiser, Wayne L ^a   Livingston, Robert B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0031720390     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3078     Document Type: Article

References (14)

1. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: A meta-analysis. Ann Intern Med 125:723-729, 1996
2. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
3. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
4. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
5. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
6. Rosenow EC III: Lung cancer: Update on screening, diagnosis, and prognosis. Consultant 35:1355-1371, 1995
7. Valdivieso M, Kraut M, Lattin P, et al: Prospective assessment of clinical trials and combined modality therapy in patients with stage III lung cancer. Proc Am Soc Clin Oncol 12:351, 1993 (abstr 1182)
8. Lau D, Ryu J, Gandara D, et al: Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: A pilot study. Int J Radiat Oncol Biol Phys 38:157-161, 1997
9. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Feld R, Abratt R, Graziano S, et al: Pretreatment minimal staging and prognostic factors of non-small cell lung cancer. Lung Cancer 17:S3-S10, 1997(suppl 1)
12. Scott C, Sause WT, Byhardt R, et al: Recursive partitioning analysis of 1592 patients on four radiation therapy oncology group studies in inoperable non-small cell lung cancer. Lung Cancer 17:859-S74, 1997 (suppl 1)
13. Crowley J: Southwest Oncology Group: Report of Studies. Lung Cancer Committee. Seattle, WA, SWOG Statistical Center, 1995
14. Volks EE: Combined modality therapy with radiation in NSCLC. Lung Cancer 18:139-140, 1997 (suppl 2)